Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model

[1]  B. de Strooper,et al.  The amyloid cascade hypothesis: are we poised for success or failure? , 2016, Journal of neurochemistry.

[2]  P. Cumming,et al.  Monitoring of chronic γ-secretase modulator treatment by serial amyloid-PET , 2015, Molecular Psychiatry.

[3]  M. Kassiou,et al.  Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study , 2015, Neurobiology of Aging.

[4]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[5]  Stefan Wiehr,et al.  Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion , 2014, Nature Medicine.

[6]  Pedro Rosa-Neto,et al.  MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research , 2014, Trends in Neurosciences.

[7]  Fabio Fiordaliso,et al.  Multifunctional Liposomes Reduce Brain β-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models , 2014, The Journal of Neuroscience.

[8]  M. Masserini,et al.  Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[9]  M. Scheinin,et al.  In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol , 2014, EJNMMI Research.

[10]  J. Hardy,et al.  A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.

[11]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[12]  P. Cumming,et al.  Cross-Sectional Comparison of Small Animal [18F]-Florbetaben Amyloid-PET between Transgenic AD Mouse Models , 2014, PloS one.

[13]  S. Gauthier,et al.  Health economic evaluation of treatments for Alzheimer′s disease: impact of new diagnostic criteria , 2014, Journal of internal medicine.

[14]  Jochen Herms,et al.  Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET , 2014, NeuroImage.

[15]  M. Scheinin,et al.  Longitudinal Amyloid Imaging in Mouse Brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 Mouse Models of Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[16]  P. Cumming,et al.  Longitudinal Assessment of Cerebral β-Amyloid Deposition in Mice Overexpressing Swedish Mutant β-Amyloid Precursor Protein Using 18F-Florbetaben PET , 2013, The Journal of Nuclear Medicine.

[17]  Maria Gregori,et al.  Nanotechnology for neurodegenerative disorders. , 2012, Maturitas.

[18]  M. Scheinin,et al.  Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Stefan Platzer,et al.  Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease , 2012, PloS one.

[20]  M. Masserini,et al.  Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. , 2011, Journal of biotechnology.

[21]  M. Masserini,et al.  Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[22]  Doriano Brogioli,et al.  Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. , 2010, Biomaterials.

[23]  Harald Hampel,et al.  Biological markers of amyloid β-related mechanisms in Alzheimer's disease , 2010, Experimental Neurology.

[24]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[25]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[26]  Ralph Myers,et al.  Small animal PET , 2002, European Neuropsychopharmacology.

[27]  M. Staufenbiel,et al.  Pathogenic Mechanisms of Alzheimer's Disease Analyzed in the APP23 Transgenic Mouse Model , 2000, Annals of the New York Academy of Sciences.

[28]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Larsen,et al.  Synthesis of [11C]iodomethane by iodination of [11C]methane , 1997 .

[30]  D. Jewett,et al.  A simple synthesis of [11C]methyl triflate. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[31]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[32]  G. Sancini,et al.  The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[33]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .